ArticleiLIVER2024
Analysis of efficacy and safety for the combination of regorafenib and PD-1 inhibitor in advanced hepatocellular carcinoma: A real-world clinical study.
Article in iLIVER, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Synergistic mechanisms and clinical translation of regorafenib combination therapies.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Immunotherapy in hepatocellular carcinoma: translating mechanistic insights into clinical advances.Clinical and experimental medicine · 2026Review
- Reversal of tumour immune evasion via enhanced MHC-Class-I antigen presentation by a dual-functional RNA regulated system.Molecular cancer · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aims: Hepatocellular carcinoma (HCC) is a prevalent and deadly disease with limited treatment options. Regorafenib, a tyrosine kinase inhibitor, has shown promise in HCC treatment but faces limitations as a monotherapy. Combining regorafenib with PD-1 inhibitor may improve efficacy and survival outcomes for patients. This retrospective analysis was conducted to explore its efficacy and safety, providing reference experience for better application of this combination therapy. Methods: This retrospective single-center study evaluated the efficacy and safety of combining regorafenib with PD-1 blockade for patients with HCC. Efficacy was evaluated according to the RECIST 1.1 evaluation criteria. Safety was assessed using CTCAE 4.0. Data was analyzed to compare survival status in different subgroups. Results: Generally, there were 76 patients with HCC elected to receive the regorafenib plus PD-1 blockade treatment during the study period. The objective response rate was 21.1% ( Conclusion: With manageable safety, regorafenib combined PD-1 inhibitor could bring survival benefits for advanced HCC who have received systemic treatment. Further, the Cox analysis showed that HBV infection, metastasis, etc. did not have significant effects on the survival benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.